drugset / Trial / NCT06895967
A Study of TAK-881 and HyQvia in Healthy Adults
RandomizedParallel-groupOpen-labelOther
Summary
The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults. Study participants will receive a single dose of TAK-881 or HyQvia on Day 1. During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
Timeline
- Start
- 2025-03-24
- Primary completion
- 2025-07-24
- Completion
- 2025-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HYQVIA | Protein / enzyme biologic | 1 g/kg | Subcutaneous |
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 1 g/kg | Subcutaneous |
Indications
No indication recorded.